Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Rheumatol. 2012 May;24(3):290-8. doi: 10.1097/BOR.0b013e32835257c5.

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.

Author information

  • 1Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. s.arends@umcg.nl

Abstract

PURPOSE OF REVIEW:

Identifying the characteristics of patients with ankylosing spondylitis (AS) before start of treatment which are able to predict a beneficial response to tumor necrosis factor-alpha (TNF-α) blocking therapy is relevant, especially in view of the high costs and potential side-effects of these agents. This review provides an overview of clinical trials and observational studies investigating baseline predictors of response after 3-6 months of TNF-α blocking therapy and baseline predictors of long-term anti-TNF-α treatment continuation in AS.

RECENT FINDINGS:

In multiple studies, increased acute phase reactants, higher disease activity, higher functional status, younger age, and HLA-B27 positivity were identified as independent baseline predictors of achieving clinical response to TNF-α blocking therapy. Increased acute phase reactants, presence of peripheral arthritis, and male sex were repeatedly identified as independent baseline predictors of anti-TNF-α treatment continuation.

SUMMARY:

Several studies using multivariate analyses identified comparable baseline predictors of response and/or continuation of TNF-α blocking therapy. The single predictors identified have, at best, moderate capacity to predict treatment response in the individual patient. The development of a prediction model may lead to a more robust instrument to support physicians in decision making on TNF-α blocking therapy in AS in daily clinical practice.

PMID:
22418743
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Write to the Help Desk